{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:18:25Z","timestamp":1793121505875,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Science Research Project of Hebei","award":["20240243"],"award-info":[{"award-number":["20240243"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-97504-3","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T04:28:17Z","timestamp":1744604897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost-effectiveness of CDK4\/6 inhibitors for second-line HR+\/HER2\u2212\u2009advanced or metastatic breast cancer in China"],"prefix":"10.1038","volume":"15","author":[{"given":"Caifeng","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sainan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"97504_CR1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.3322\/caac.21834","volume":"74","author":"FAO Bray","year":"2024","unstructured":"Bray, F. A. O. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 74, 1542\u20134863. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"Cancer J. Clin."},{"key":"97504_CR2","doi-asserted-by":"publisher","unstructured":"Han, B. et al. Cancer incidence and mortality in China, 2022. J. Natl. Cancer Center 4, 47\u201353 https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006 (2024).","DOI":"10.1016\/j.jncc.2024.01.006"},{"key":"97504_CR3","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/cac2.12207","volume":"41","author":"S Lei","year":"2021","unstructured":"Lei, S. et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun. (London England). 41, 1183\u20131194. https:\/\/doi.org\/10.1002\/cac2.12207 (2021).","journal-title":"Cancer Commun. (London England)"},{"key":"97504_CR4","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/s1470-2045(13)70567-9","volume":"15","author":"L Fan","year":"2014","unstructured":"Fan, L. et al. Breast cancer in China. Lancet Oncol. 15, e279\u2013289. https:\/\/doi.org\/10.1016\/s1470-2045(13)70567-9 (2014).","journal-title":"Lancet Oncol."},{"key":"97504_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","volume":"45","author":"E Hamilton","year":"2016","unstructured":"Hamilton, E. & Infante, J. R. Targeting CDK4\/6 in patients with cancer. Cancer Treat. Rev. 45, 129\u2013138. https:\/\/doi.org\/10.1016\/j.ctrv.2016.03.002 (2016).","journal-title":"Cancer Treat. Rev."},{"key":"97504_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar, U., Witkiewicz, A. K., Turner, N. C. & Knudsen, E. S. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov.. 14, 130\u2013146. https:\/\/doi.org\/10.1038\/nrd4504 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"97504_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","volume":"18","author":"RS Finn","year":"2016","unstructured":"Finn, R. S., Aleshin, A. & Slamon, D. J. Targeting the cyclin-dependent kinases (CDK) 4\/6 in Estrogen receptor-positive breast cancers. Breast Cancer Res. 18, 17. https:\/\/doi.org\/10.1186\/s13058-015-0661-5 (2016).","journal-title":"Breast Cancer Res."},{"key":"97504_CR8","doi-asserted-by":"publisher","first-page":"188912","DOI":"10.1016\/j.bbcan.2023.188912","volume":"1878","author":"S Zhang","year":"2023","unstructured":"Zhang, S., Xu, Q., Sun, W., Zhou, J. & Zhou, J. Immunomodulatory effects of CDK4\/6 inhibitors. Biochim. Et Biophys. Acta Rev. Cancer. 1878, 188912. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188912 (2023).","journal-title":"Biochim. Et Biophys. Acta Rev. Cancer"},{"key":"97504_CR9","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1158\/1078-0432.Ccr-22-0305","volume":"28","author":"M Cristofanilli","year":"2022","unstructured":"Cristofanilli, M. et al. Overall survival with Palbociclib and fulvestrant in women with HR+\/HER2- ABC: Updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 28, 3433\u20133442. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-0305 (2022).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"97504_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli, M. et al. Fulvestrant plus Palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17, 425\u2013439. https:\/\/doi.org\/10.1016\/s1470-2045(15)00613-0 (2016).","journal-title":"Lancet Oncol."},{"key":"97504_CR11","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner, N. C. et al. Overall survival with Palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379, 1926\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1810527 (2018).","journal-title":"N. Engl. J. Med."},{"key":"97504_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon, D. J. et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N. Engl. J. Med. 382, 514\u2013524. https:\/\/doi.org\/10.1056\/NEJMoa1911149 (2020).","journal-title":"N. Engl. J. Med."},{"key":"97504_CR13","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/jco.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon, D. J. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-Positive, human epidermal growth factor receptor 2-Negative advanced breast cancer: MONALEESA-3. J. Clin. Oncol. Off.J. Am. Soc. Clin. Oncol. 36, 2465\u20132472. https:\/\/doi.org\/10.1200\/jco.2018.78.9909 (2018).","journal-title":"J. Clin. Oncol. Off.J. Am. Soc. Clin. Oncol."},{"key":"97504_CR14","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","volume":"32","author":"DJ Slamon","year":"2021","unstructured":"Slamon, D. J. et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: Updated overall survival. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 32, 1015\u20131024. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.353 (2021).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"97504_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge, G. W. Jr. et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial. JAMA Oncol. 6, 116\u2013124. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4782 (2020).","journal-title":"JAMA Oncol."},{"key":"97504_CR16","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/jco.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge, G. W. Jr. et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 35, 2875\u20132884. https:\/\/doi.org\/10.1200\/jco.2017.73.7585 (2017).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"97504_CR17","doi-asserted-by":"publisher","first-page":"175883592110005","DOI":"10.1177\/17588359211000593","volume":"13","author":"AM Buehler","year":"2021","unstructured":"Buehler, A. M., Castilho, G., Dionne, P. A. & Stefani, S. Cost-effectiveness of ribociclib plus letrozole versus Palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+\/HER2- locally advanced or metastatic breast cancer: A Brazilian private payer perspective. Therapeutic Adv. Med. Oncol. 13, 17588359211000593. https:\/\/doi.org\/10.1177\/17588359211000593 (2021).","journal-title":"Therapeutic Adv. Med. Oncol."},{"key":"97504_CR18","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/s0140-6736(19)32136-1","volume":"394","author":"W Yip","year":"2019","unstructured":"Yip, W. et al. 10 years of health-care reform in China: Progress and gaps in universal health coverage. Lancet (London England). 394, 1192\u20131204. https:\/\/doi.org\/10.1016\/s0140-6736(19)32136-1 (2019).","journal-title":"Lancet (London England)"},{"key":"97504_CR19","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","volume":"23","author":"BS Woods","year":"2020","unstructured":"Woods, B. S., Sideris, E., Palmer, S., Latimer, N. & Soares, M. Partitioned survival and state transition models for healthcare decision making in oncology: Where are we now? Value Health J. Int. Soc. Pharmacoecon. Outcomes Res. 23, 1613\u20131621. https:\/\/doi.org\/10.1016\/j.jval.2020.08.2094 (2020).","journal-title":"Value Health J. Int. Soc. Pharmacoecon. Outcomes Res."},{"key":"97504_CR20","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/cncr.27819","volume":"119","author":"AJ Tevaarwerk","year":"2013","unstructured":"Tevaarwerk, A. J. et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: Little evidence of improvement over the past 30 years. Cancer 119, 1140\u20131148. https:\/\/doi.org\/10.1002\/cncr.27819 (2013).","journal-title":"Cancer"},{"key":"97504_CR21","volume-title":"China Guidelines for Pharmacoeconomic Evaluations","author":"G Liu","year":"2020","unstructured":"Liu, G., Wu, H. S., Wu, J., Dong, J. & Li, C. H. China Guidelines for Pharmacoeconomic Evaluations (China Market, 2020)."},{"key":"97504_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot, P., Ades, A. E., Ouwens, M. J. & Welton, N. J. Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol. 12, 9. https:\/\/doi.org\/10.1186\/1471-2288-12-9 (2012).","journal-title":"BMC Med. Res. Methodol."},{"key":"97504_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu, N., Zhou, Y. & Lee, J. J. IPDfromKM: Reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol. 21, 111. https:\/\/doi.org\/10.1186\/s12874-021-01308-8 (2021).","journal-title":"BMC Med. Res. Methodol."},{"key":"97504_CR24","doi-asserted-by":"crossref","unstructured":"Latimer, N. R. in Survival analysis for economic evaluations alongside clinical Trials - Extrapolation with Patient-Level data (National Institute for health and care Excellence, 2013) (NICE) copyright \u00a9 2013 National Institute for health and clinical excellence, unless otherwise stated. All Rights Reserved.","DOI":"10.1177\/0272989X12472398"},{"key":"97504_CR25","unstructured":"National Physical Fitness Monitoring Center Issued the Fifth National Physical Fitness Monitoring Communique (General administration of sport of China, 2022). www.sport.gov.cn\/n315\/n329\/c24335066\/content.html."},{"key":"97504_CR26","doi-asserted-by":"publisher","first-page":"658054","DOI":"10.3389\/fonc.2021.658054","volume":"11","author":"E Jeong","year":"2021","unstructured":"Jeong, E., Wang, C., Wilson, L. & Zhong, L. Cost-effectiveness of adding ribociclib to endocrine therapy for patients with HR-positive, HER2-negative advanced breast cancer among premenopausal or perimenopausal women. Front. Oncol. 11, 658054. https:\/\/doi.org\/10.3389\/fonc.2021.658054 (2021).","journal-title":"Front. Oncol."},{"key":"97504_CR27","doi-asserted-by":"publisher","first-page":"1049947","DOI":"10.3389\/fpubh.2023.1049947","volume":"11","author":"M Zhan","year":"2023","unstructured":"Zhan, M. et al. Cost-effectiveness analysis of trastuzumab Deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04. Front. Public. Health. 11, 1049947. https:\/\/doi.org\/10.3389\/fpubh.2023.1049947 (2023).","journal-title":"Front. Public. Health"},{"key":"97504_CR28","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1007\/s12325-022-02079-4","volume":"39","author":"T Zhou","year":"2022","unstructured":"Zhou, T. et al. Economic evaluation of sintilimab plus bevacizumab versus Sorafenib as a first-line treatment for unresectable hepatocellular carcinoma. Adv. Ther. 39, 2165\u20132177. https:\/\/doi.org\/10.1007\/s12325-022-02079-4 (2022).","journal-title":"Adv. Ther."},{"key":"97504_CR29","doi-asserted-by":"publisher","first-page":"11382","DOI":"10.21037\/apm-21-2412","volume":"10","author":"H Wang","year":"2021","unstructured":"Wang, H., Wang, Y., Gong, R., Geng, Y. & Li, L. Cost-effectiveness of Pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China. Ann. Palliat. Med. 10, 11382\u201311393. https:\/\/doi.org\/10.21037\/apm-21-2412 (2021).","journal-title":"Ann. Palliat. Med."},{"key":"97504_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12733","author":"H Ding","year":"2017","unstructured":"Ding, H. et al. Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer. Eur. J. Cancer Care.  https:\/\/doi.org\/10.1111\/ecc.12733 (2017).","journal-title":"Eur. J. Cancer Care"},{"key":"97504_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s40425-018-0440-9","volume":"6","author":"B Wu","year":"2018","unstructured":"Wu, B., Zhang, Q. & Sun, J. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. J. Immunother. Cancer. 6, 124. https:\/\/doi.org\/10.1186\/s40425-018-0440-9 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"97504_CR32","doi-asserted-by":"publisher","first-page":"658747","DOI":"10.3389\/fmed.2021.658747","volume":"8","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Rui, M., Guan, X., Cao, Y. & Chen, P. Cost-effectiveness analysis of abemaciclib plus fulvestrant in the second-line treatment of women with HR+\/HER2- advanced or metastatic breast cancer: A US payer perspective. Front. Med. 8, 658747. https:\/\/doi.org\/10.3389\/fmed.2021.658747 (2021).","journal-title":"Front. Med."},{"key":"97504_CR33","doi-asserted-by":"publisher","first-page":"514","DOI":"10.18553\/jmcp.2018.24.6.514","volume":"24","author":"R Mistry","year":"2018","unstructured":"Mistry, R. et al. Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+\/HER2- advanced or metastatic breast cancer: A U.S. Payer perspective. J. Managed Care Specialty Pharm. 24, 514\u2013523. https:\/\/doi.org\/10.18553\/jmcp.2018.24.6.514 (2018).","journal-title":"J. Managed Care Specialty Pharm."},{"key":"97504_CR34","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"A Lloyd","year":"2006","unstructured":"Lloyd, A., Nafees, B., Narewska, J., Dewilde, S. & Watkins, J. Health state utilities for metastatic breast cancer. Br. J. Cancer. 95, 683\u2013690. https:\/\/doi.org\/10.1038\/sj.bjc.6603326 (2006).","journal-title":"Br. J. Cancer"},{"key":"97504_CR35","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1016\/j.clbc.2021.01.019","volume":"21","author":"X Huang","year":"2021","unstructured":"Huang, X. et al. First-line treatment with ribociclib plus endocrine therapy for premenopausal women with Hormone-receptor-positive advanced breast cancer: A cost-effectiveness analysis. Clin. Breast. Cancer. 21, e479\u2013e488. https:\/\/doi.org\/10.1016\/j.clbc.2021.01.019 (2021).","journal-title":"Clin. Breast. Cancer"},{"key":"97504_CR36","doi-asserted-by":"publisher","first-page":"504","DOI":"10.2165\/00019053-199610050-00008","volume":"10","author":"R Launois","year":"1996","unstructured":"Launois, R., Reboul-Marty, J., Henry, B. & Bonneterre, J. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus Paclitaxel versus Vinorelbine. PharmacoEconomics 10, 504\u2013521. https:\/\/doi.org\/10.2165\/00019053-199610050-00008 (1996).","journal-title":"PharmacoEconomics"},{"key":"97504_CR37","doi-asserted-by":"crossref","unstructured":"Briggs, A., Sculpher, M. & Claxton, K. Modelling methods for health economic evaluation. (2006).","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"97504_CR38","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40273-023-01245-y","volume":"41","author":"PP Masurkar","year":"1996","unstructured":"Masurkar, P. P., Damgacioglu, H., Deshmukh, A. A. & Trivedi, M. V. Cost effectiveness of CDK4\/6 inhibitors in the first-line treatment of HR+\/HER2- metastatic breast cancer in postmenopausal women in the USA. PharmacoEconomics 41, 709\u2013718 https:\/\/doi.org\/10.1007\/s40273-023-01245-y (2023).","journal-title":"PharmacoEconomics"},{"key":"97504_CR39","doi-asserted-by":"publisher","unstructured":"Shi, F., He, Z., Su, H., Wang, L. & Han, S. Economic evaluation of Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China. 13, 961347. https:\/\/doi.org\/10.3389\/fphar.2022.961347 (2022).","DOI":"10.3389\/fphar.2022.961347"},{"key":"97504_CR40","doi-asserted-by":"publisher","first-page":"e067975","DOI":"10.1136\/bmj-2021-067975","volume":"376","author":"D Husereau","year":"2022","unstructured":"Husereau, D. et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. BMJ (Clin. Res. ed.). 376, e067975. https:\/\/doi.org\/10.1136\/bmj-2021-067975 (2022).","journal-title":"BMJ (Clin. Res. ed.)"},{"key":"97504_CR41","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3111\/13696998.2016.1151431","volume":"19","author":"C Beauchemin","year":"2016","unstructured":"Beauchemin, C., Letarte, N., Mathurin, K., Yelle, L. & Lachaine, J. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada. J. Med. Econ. 19, 619\u2013629. https:\/\/doi.org\/10.3111\/13696998.2016.1151431 (2016).","journal-title":"J. Med. Econ."},{"key":"97504_CR42","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s40273-021-01027-4","volume":"39","author":"D Stellato","year":"1996","unstructured":"Stellato, D., Thabane, M. E., Park, J., Chandiwana, D. & Delea, T. E. Cost effectiveness of ribociclib in combination with fulvestrant for the treatment of postmenopausal women with HR+\/HER2- advanced breast cancer who have received no or only one prior line of endocrine therapy: A Canadian healthcare perspective. PharmacoEconomics 39, 1045\u20131058 https:\/\/doi.org\/10.1007\/s40273-021-01027-4  (2021).","journal-title":"PharmacoEconomics"},{"key":"97504_CR43","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2217\/imt-2020-0237","volume":"13","author":"W Jiang","year":"2021","unstructured":"Jiang, W. et al. Cost-effectiveness analysis of ribociclib plus fulvestrant for hormone receptor-positive\/human EGF receptor 2-negative breast cancer. Immunotherapy 13, 661\u2013668. https:\/\/doi.org\/10.2217\/imt-2020-0237 (2021).","journal-title":"Immunotherapy"},{"key":"97504_CR44","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.clinthera.2019.04.033","volume":"41","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Cost-effectiveness analysis of adding Palbociclib as a second-line endocrine therapy for HR(+)\/HER2(-) metastatic breast cancer from the US and Chinese perspectives. Clin. Ther. 41, 1175\u20131185. https:\/\/doi.org\/10.1016\/j.clinthera.2019.04.033 (2019).","journal-title":"Clin. Ther."},{"key":"97504_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2018.10.004","volume":"43","author":"X Wan","year":"2019","unstructured":"Wan, X. et al. Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China. Breast (Edinburgh Scotland). 43, 1\u20136. https:\/\/doi.org\/10.1016\/j.breast.2018.10.004 (2019).","journal-title":"Breast (Edinburgh Scotland)"},{"key":"97504_CR46","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"SA Im","year":"2019","unstructured":"Im, S. A. et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N. Engl. J. Med. 381, 307\u2013316. https:\/\/doi.org\/10.1056\/NEJMoa1903765 (2019).","journal-title":"N. Engl. J. Med."},{"key":"97504_CR47","unstructured":"Woods, B., Palmer, S. E., Latimer, S. & Soares, N. M. NICE DSU technical support document 19: Partitioned survival analysis for decision modelling in health care: A critical review. (2017)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97504-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97504-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97504-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T14:11:05Z","timestamp":1750860665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97504-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97504"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97504-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: The Funding section in the original version of this Article was incorrect. The Funding section now reads: \u201cThis work was supported by the Medical Science Research Project of Hebei (20240243).\u201d","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The data of the PFS\/OS was based on previously published trials, and ethics approval or specific consent procedures were not applicable for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"12765"}}